Diligence memo · auto-generated · as of July 2, 2026
CERo Therapeutics, Inc.
CERo Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
CERo Therapeutics, Inc. operates in Pharma, based in SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CERo Therapeutics, Inc. has raised $45M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $43M on 2019-11-14.
Most recent recorded round closed around 2019-11-14.
Valuation (modeled)modeled
Provath models CERo Therapeutics, Inc. at approximately $1.5B (range $140M–$4.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.75× the median modeled value of Series C Pharma companies in 2019–2021 (7 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 33 months.
Last raise 6.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 30.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharma peers (310 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Ansun Biopharma, Inc., Integrated Oncology Network Holdco, LLC, Tallac Therapeutics, Inc., Elevation Oncology, Inc., Levo Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.